Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey

[1] Kinross P(2020)Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020 Eurosurveillance 25 2000285-1826

[2] Suetens C(2020)The efficiency in the ordinary hospital bed management in Italy: an in-depth analysis of intensive care unit in the areas affected by COVID-19 before the outbreak PLoS ONE 15 e0239249-340

[3] Gomes Dias J(2017)GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses Sci Rep 7 43395-52

[4] Pecoraro F(2019)Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase Antiviral Res 169 104541-1578

[5] Clemente F(2020)Remdesivir for the treatment of Covid-19 — final report N Engl J Med 383 1813-1164

[6] Luzi D(2021)The effectiveness and safety of remdesivir for the treatment of patients with COVID-19: a systematic review and meta-analysis Antiinfective Agents 19 333-119

[7] Lo MK(2021)Comparative effectiveness of pharmacological interventions for Covid-19: a systematic review and network meta-analysis Front Pharmacol 12 16-1766

[8] Jordan R(2021)Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis BMJ Support Palliat Care 11 45-131

[9] Arvey A(2020)Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Lancet 395 1569-undefined

[10] Brown AJ(2021)The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization Vaccine 39 1157-undefined

[1] Kinross P(2020)Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020 Eurosurveillance 25 2000285-1826

[2] Suetens C(2020)The efficiency in the ordinary hospital bed management in Italy: an in-depth analysis of intensive care unit in the areas affected by COVID-19 before the outbreak PLoS ONE 15 e0239249-340

[3] Gomes Dias J(2017)GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses Sci Rep 7 43395-52

[4] Pecoraro F(2019)Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase Antiviral Res 169 104541-1578

[5] Clemente F(2020)Remdesivir for the treatment of Covid-19 — final report N Engl J Med 383 1813-1164

[6] Luzi D(2021)The effectiveness and safety of remdesivir for the treatment of patients with COVID-19: a systematic review and meta-analysis Antiinfective Agents 19 333-119

[7] Lo MK(2021)Comparative effectiveness of pharmacological interventions for Covid-19: a systematic review and network meta-analysis Front Pharmacol 12 16-1766

[8] Jordan R(2021)Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis BMJ Support Palliat Care 11 45-131

[9] Arvey A(2020)Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Lancet 395 1569-undefined

[10] Brown AJ(2021)The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization Vaccine 39 1157-undefined